Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Concerns regarding use of patient-reported outcomes in biomarker studies of chemotherapy-induced peripheral neuropathy.

Hertz DL.

Pharmacogenomics J. 2019 Oct;19(5):411-416. doi: 10.1038/s41397-019-0093-1. Epub 2019 Aug 9. Review. No abstract available.

PMID:
31395959
2.

Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview.

Chan A, Hertz DL, Morales M, Adams EJ, Gordon S, Tan CJ, Staff NP, Kamath J, Oh J, Shinde S, Pon D, Dixit N, D'Olimpio J, Dumitrescu C, Gobbo M, Kober K, Mayo S, Pang L, Subbiah I, Beutler AS, Peters KB, Loprinzi C, Lustberg MB.

Support Care Cancer. 2019 Oct;27(10):3729-3737. doi: 10.1007/s00520-019-04987-8. Epub 2019 Jul 30. Review.

PMID:
31363906
3.

Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole.

Dempsey JM, Kidwell KM, Gersch CL, Pesch AM, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM, Hertz DL.

Pharmacogenomics. 2019 Jun;20(8):571-580. doi: 10.2217/pgs-2019-0020.

PMID:
31190621
4.

Impact of CYP3A5 phenotype on tacrolimus concentrations after sublingual and oral administration in lung transplant.

Pasternak AL, Kidwell KM, Dempsey JM, Gersch CL, Pesch A, Sun Y, Rae JM, Hertz DL, Park JM.

Pharmacogenomics. 2019 Apr;20(6):421-432. doi: 10.2217/pgs-2019-0002. Epub 2019 Apr 15.

PMID:
30983501
5.

Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.

Kamdem LK, Xi J, Clark BL, Gregory BJ, Kidwell KM, Storniolo AM, Stearns V, Hayes DF, Gersch CL, Rae JM, Henry NL, Hertz DL.

Breast Cancer Res Treat. 2019 Jun;175(2):297-303. doi: 10.1007/s10549-019-05158-3. Epub 2019 Feb 12.

PMID:
30747308
6.

Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure.

Marcath LA, Kidwell KM, Robinson AC, Vangipuram K, Burness ML, Griggs JJ, Poznak CV, Schott AF, Hayes DF, Henry NL, Hertz DL.

Pharmacogenomics. 2019 Jan;20(2):95-104. doi: 10.2217/pgs-2018-0162. Epub 2018 Dec 6.

PMID:
30520341
7.

Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials.

Marcath LA, Coe TD, Hoylman EK, Redman BG, Hertz DL.

BMC Cancer. 2018 Nov 22;18(1):1155. doi: 10.1186/s12885-018-5076-0.

8.

Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy.

Sun Y, Kim JH, Vangipuram K, Hayes DF, Smith EML, Yeomans L, Henry NL, Stringer KA, Hertz DL.

Breast Cancer Res Treat. 2018 Oct;171(3):657-666. doi: 10.1007/s10549-018-4862-3. Epub 2018 Jun 26.

9.

Comparison of Nine Tools for Screening Drug-Drug Interactions of Oral Oncolytics.

Marcath LA, Xi J, Hoylman EK, Kidwell KM, Kraft SL, Hertz DL.

J Oncol Pract. 2018 Jun;14(6):e368-e374. doi: 10.1200/JOP.18.00086. Epub 2018 May 22.

PMID:
29787332
10.

Drug interaction screening in SWOG clinical trials.

Hertz DL, Siden R, Modlin J, Gabel LL, Wong SF.

Am J Health Syst Pharm. 2018 May 15;75(10):607-612. doi: 10.2146/ajhp170449.

11.

Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy.

Hertz DL, Kidwell KM, Vangipuram K, Li F, Pai MP, Burness M, Griggs JJ, Schott AF, Van Poznak C, Hayes DF, Lavoie Smith EM, Henry NL.

Clin Cancer Res. 2018 Aug 1;24(15):3602-3610. doi: 10.1158/1078-0432.CCR-18-0656. Epub 2018 Apr 27.

12.

CYP3A pharmacogenetic association with tacrolimus pharmacokinetics differs based on route of drug administration.

Pasternak AL, Zhang L, Hertz DL.

Pharmacogenomics. 2018 Apr;19(6):563-576. doi: 10.2217/pgs-2018-0003. Epub 2018 Apr 9. Review.

PMID:
29629825
13.

Attempted replication of SNPs in RANKL and OPG with musculoskeletal adverse events during aromatase inhibitor treatment for breast cancer.

Dempsey JM, Xi J, Henry NL, Rae JM, Hertz DL.

Physiol Genomics. 2018 Feb 1;50(2):98-99. doi: 10.1152/physiolgenomics.00085.2017. Epub 2017 Dec 8.

14.

Germline genetic variants with implications for disease risk and therapeutic outcomes.

Pasternak AL, Ward KM, Luzum JA, Ellingrod VL, Hertz DL.

Physiol Genomics. 2017 Oct 1;49(10):567-581. doi: 10.1152/physiolgenomics.00035.2017. Epub 2017 Sep 8. Review.

15.

Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment.

Marcath LA, Deal AM, Van Wieren E, Danko W, Walko CM, Ibrahim JG, Weck KE, Jones DR, Desta Z, McLeod HL, Carey LA, Irvin WJ Jr, Hertz DL.

Pharmacogenet Genomics. 2017 Nov;27(11):402-409. doi: 10.1097/FPC.0000000000000311.

16.

Institutional profile of pharmacogenetics within University of Michigan College of Pharmacy.

Hertz DL, Luzum JA, Pasternak AL, Ward KM, Zhu HJ, Rae JM, Ellingrod VL.

Pharmacogenomics. 2017 Jul 26. doi: 10.2217/pgs-2017-0107. [Epub ahead of print]

PMID:
28745551
17.

CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.

Hertz DL, Kidwell KM, Hilsenbeck SG, Oesterreich S, Osborne CK, Philips S, Chenault C, Hartmaier RJ, Skaar TC, Sikora MJ, Rae JM.

Breast Cancer Res Treat. 2017 Nov;166(1):277-287. doi: 10.1007/s10549-017-4400-8. Epub 2017 Jul 20.

18.

Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients.

Hertz DL, Speth KA, Kidwell KM, Gersch CL, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM.

Breast Cancer Res Treat. 2017 Oct;165(3):659-668. doi: 10.1007/s10549-017-4346-x. Epub 2017 Jun 22.

19.

Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer.

Dolan ME, El Charif O, Wheeler HE, Gamazon ER, Ardeshir-Rouhani-Fard S, Monahan P, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Fung C, Kim J, Fossa SD, Hertz DL, Mushiroda T, Kubo M, Einhorn LH, Cox NJ, Travis LB; Platinum Study Group.

Clin Cancer Res. 2017 Oct 1;23(19):5757-5768. doi: 10.1158/1078-0432.CCR-16-3224. Epub 2017 Jun 13.

20.

Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients.

Hertz DL, Henry NL, Rae JM.

Pharmacogenomics. 2017 Apr;18(5):481-499. doi: 10.2217/pgs-2016-0205. Epub 2017 Mar 27. Review.

21.

Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.

Ahern TP, Hertz DL, Damkier P, Ejlertsen B, Hamilton-Dutoit SJ, Rae JM, Regan MM, Thompson AM, Lash TL, Cronin-Fenton DP.

Am J Epidemiol. 2017 Jan 15;185(2):75-85. doi: 10.1093/aje/kww178. Epub 2016 Dec 17. Review.

22.

Individualized Tamoxifen Dose Escalation-Response.

Hertz DL, Rae JM.

Clin Cancer Res. 2016 Dec 15;22(24):6301. No abstract available.

23.

Vincristine-induced peripheral neuropathy in pediatric cancer patients.

Mora E, Smith EM, Donohoe C, Hertz DL.

Am J Cancer Res. 2016 Nov 1;6(11):2416-2430. eCollection 2016. Review.

24.

Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer.

Hertz DL, Kidwell KM, Seewald NJ, Gersch CL, Desta Z, Flockhart DA, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM.

Pharmacogenomics J. 2017 Dec;17(6):521-527. doi: 10.1038/tpj.2016.60. Epub 2016 Aug 23.

25.

ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors.

Hertz DL, Henry NL, Kidwell KM, Thomas D, Goddard A, Azzouz F, Speth K, Li L, Banerjee M, Thibert JN, Kleer CG, Stearns V, Hayes DF, Skaar TC, Rae JM.

Physiol Genomics. 2016 Sep 1;48(9):688-98. doi: 10.1152/physiolgenomics.00065.2016. Epub 2016 Aug 19.

26.

One step at a time: CYP2D6 guided tamoxifen treatment awaits convincing evidence of clinical validity.

Hertz DL, Rae JM.

Pharmacogenomics. 2016 Jun;17(8):823-6. doi: 10.2217/pgs-2016-0059. Epub 2016 Jun 1. No abstract available.

27.

Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.

Hertz DL, Deal A, Ibrahim JG, Walko CM, Weck KE, Anderson S, Magrinat G, Olajide O, Moore S, Raab R, Carrizosa DR, Corso S, Schwartz G, Graham M, Peppercorn JM, Jones DR, Desta Z, Flockhart DA, Evans JP, McLeod HL, Carey LA, Irvin WJ Jr.

Oncologist. 2016 Jul;21(7):795-803. doi: 10.1634/theoncologist.2015-0480. Epub 2016 May 25.

28.

Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.

Hertz DL, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, Patel J, Halabi S, Furukawa Y, Wheeler HE, Sibley AB, Lassiter C, Weisman L, Watson D, Krens SD, Mulkey F, Renn CL, Small EJ, Febbo PG, Shterev I, Kroetz DL, Friedman PN, Mahoney JF, Carducci MA, Kelley MJ, Nakamura Y, Kubo M, Dorsey SG, Dolan ME, Morris MJ, Ratain MJ, McLeod HL.

Clin Cancer Res. 2016 Oct 1;22(19):4890-4900. Epub 2016 May 3.

29.

Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of Utility.

Hertz DL, Rae JM.

Clin Cancer Res. 2016 Jul 1;22(13):3121-3. doi: 10.1158/1078-0432.CCR-16-0370. Epub 2016 Mar 24.

30.

Pharmacogenetic Predictors of Response.

Hertz DL, Rae JM.

Adv Exp Med Biol. 2016;882:191-215. doi: 10.1007/978-3-319-22909-6_8. Review.

PMID:
26987536
31.

Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226.

Hertz DL, Barlow WE, Kidwell KM, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Livingston RB, Gralow J, Hayes DF, Hortobagyi GN, Mehta RS, Rae JM.

Br J Clin Pharmacol. 2016 Jun;81(6):1134-41. doi: 10.1111/bcp.12904. Epub 2016 Apr 8.

32.

Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines.

Hertz DL, Caram MV, Kidwell KM, Thibert JN, Gersch C, Seewald NJ, Smerage J, Rubenfire M, Henry NL, Cooney KA, Leja M, Griggs JJ, Rae JM.

Pharmacogenomics. 2016 Feb;17(3):231-40. doi: 10.2217/pgs.15.162. Epub 2016 Jan 22.

33.

Integrated patient and tumor genetic testing for individualized cancer therapy.

Hertz DL, McLeod HL.

Clin Pharmacol Ther. 2016 Feb;99(2):143-6. doi: 10.1002/cpt.294. Epub 2015 Nov 25.

PMID:
26537014
34.

Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses.

Hertz DL, Kidwell KM, Thibert JN, Gersch C, Regan MM, Skaar TC, Henry NL, Hayes DF, Van Poznak CH, Rae JM.

Mol Oncol. 2015 Nov;9(9):1868-76. doi: 10.1016/j.molonc.2015.07.002. Epub 2015 Jul 29.

35.

Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer.

Caram MEV, Guo C, Leja M, Smerage J, Henry NL, Giacherio D, Rubenfire M, Schott A, Davis M, Hayes DF, Van Poznak C, Cooney KA, Hertz DL, Banerjee M, Griggs JJ.

Breast Cancer Res Treat. 2015 Jul;152(1):163-172. doi: 10.1007/s10549-015-3454-8. Epub 2015 Jun 7.

PMID:
26050157
36.

In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles.

Hertz DL, Snavely AC, McLeod HL, Walko CM, Ibrahim JG, Anderson S, Weck KE, Magrinat G, Olajide O, Moore S, Raab R, Carrizosa DR, Corso S, Schwartz G, Peppercorn JM, Evans JP, Jones DR, Desta Z, Flockhart DA, Carey LA, Irvin WJ Jr.

Br J Clin Pharmacol. 2015 Nov;80(5):1122-30. doi: 10.1111/bcp.12665. Epub 2015 Aug 2.

37.

Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).

Patel JN, Jiang C, Hertz DL, Mulkey FA, Owzar K, Halabi S, Ratain MJ, Friedman PN, Small EJ, Carducci MA, Mahoney JF, Kelley MJ, Morris MJ, Kelly WK, McLeod HL.

Cancer. 2015 Apr 1;121(7):1025-31. doi: 10.1002/cncr.29169. Epub 2014 Nov 21.

38.

Pharmacogenetics of cancer drugs.

Hertz DL, Rae J.

Annu Rev Med. 2015;66:65-81. doi: 10.1146/annurev-med-053013-053944. Epub 2014 Oct 29. Review.

PMID:
25386932
39.

Using pharmacogene polymorphism panels to detect germline pharmacodynamic markers in oncology.

Hertz DL, McLeod HL.

Clin Cancer Res. 2014 May 15;20(10):2530-40. doi: 10.1158/1078-0432.CCR-13-2780.

40.

Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy.

Hertz DL, Roy S, Jack J, Motsinger-Reif AA, Drobish A, Clark LS, Carey LA, Dees EC, McLeod HL.

Breast Cancer Res Treat. 2014 May;145(1):245-54. doi: 10.1007/s10549-014-2910-1. Epub 2014 Apr 6.

41.

Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity.

McWhinney-Glass S, Winham SJ, Hertz DL, Yen Revollo J, Paul J, He Y, Brown R, Motsinger-Reif AA, McLeod HL; Scottish Gynaecological Clinical Trials Group.

Clin Cancer Res. 2013 Oct 15;19(20):5769-76. doi: 10.1158/1078-0432.CCR-13-0774. Epub 2013 Aug 20.

42.

Germline pharmacogenetics of paclitaxel for cancer treatment.

Hertz DL.

Pharmacogenomics. 2013 Jul;14(9):1065-84. doi: 10.2217/pgs.13.90. Review.

PMID:
23837481
43.

Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity.

Hertz DL, McLeod HL.

J Hum Genet. 2013 Jun;58(6):346-52. doi: 10.1038/jhg.2013.42. Epub 2013 May 16. Review.

PMID:
23677053
44.

Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.

Krens SD, McLeod HL, Hertz DL.

Pharmacogenomics. 2013 Apr;14(5):555-74. doi: 10.2217/pgs.13.33.

45.

CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel.

Hertz DL, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, McLeod HL, Carey LA, Dees EC.

Ann Oncol. 2013 Jun;24(6):1472-8. doi: 10.1093/annonc/mdt018. Epub 2013 Feb 14.

46.

Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure.

Hertz DL, Walko CM, Bridges AS, Hull JH, Herendeen J, Rollins K, Watkins PB, Dees EC.

Br J Clin Pharmacol. 2012 Jul;74(1):197-200. doi: 10.1111/j.1365-2125.2012.04165.x.

47.

Tamoxifen and CYP2D6: a contradiction of data.

Hertz DL, McLeod HL, Irvin WJ Jr.

Oncologist. 2012;17(5):620-30. doi: 10.1634/theoncologist.2011-0418. Epub 2012 Apr 24. Review.

48.

CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.

Hertz DL, Motsinger-Reif AA, Drobish A, Winham SJ, McLeod HL, Carey LA, Dees EC.

Breast Cancer Res Treat. 2012 Jul;134(1):401-10. doi: 10.1007/s10549-012-2054-0. Epub 2012 Apr 18.

49.

Pharmacogenetics of breast cancer therapies.

Hertz DL, McLeod HL, Hoskins JM.

Breast. 2009 Oct;18 Suppl 3:S59-63. doi: 10.1016/S0960-9776(09)70275-9. Review.

PMID:
19914545

Supplemental Content

Loading ...
Support Center